Keros Therapeutics, Inc. KROS
Set alert
As of Nov 2, 2:37 PM ET
- YTD
- -48.04%
- 1 year
- -30.49%
- Open
- 11.12
- Prev close
- 11.04
- Mkt cap
- 209.87M
- Vol
- 74.19K
- Avg vol
- 188.77K
- EPS
- -3.22
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.53
- High
- 11.39
- Forward P/E
- -3.00
- Beta
- 1.24
- Short ratio
- 5.28
- Inst. own
- 100.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 55.00
- 200-d avg
- 53.85
- 1y target
- 43.55
News
1 week ago marketbeat.com
Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage
Keros Therapeutics NASDAQ: KROS is repositioning its pipeline around rinvatercept, a skeletal-muscle regeneration candidate being developed for neuromuscular diseases, while its partnered program…
4 weeks ago defenseworld.net
Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)
Keros Therapeutics (NASDAQ: KROS - Get Free Report) and Upstream Bio (NASDAQ: UPB - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two…
1 month ago zacks.com
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
-
1 month ago benzinga.com
Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial
ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis ("MF") and anemia on concurrent…
1 month ago globenewswire.com
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel…
-
1 month ago benzinga.com
Keros Therapeutics Doses First Patient In Phase 2 Clinical Study Of Rinvatercept In Patients With Duchenne Muscular Dystrophy
Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with…
1 month ago globenewswire.com
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel…
-
1 month ago benzinga.com
Keros Therapeutics Reveals $5M Share Repurchase Authorization
Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of
1 month ago globenewswire.com
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and…
2 months ago zacks.com
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?
2 months ago defenseworld.net
Hsbc Holdings PLC Makes New $761,000 Investment in Keros Therapeutics, Inc. $KROS
Hsbc Holdings PLC acquired a new position in Keros Therapeutics, Inc. (NASDAQ: KROS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The…
2 months ago zacks.com
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.
2 months ago zacks.com
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.
2 months ago defenseworld.net
Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP lifted its holdings in Keros Therapeutics, Inc. (NASDAQ: KROS) by 453.9% during the undefined quarter, according to the company in its most recent Form 13F filing with…
2 months ago defenseworld.net
Keros Therapeutics, Inc. $KROS Shares Acquired by Empowered Funds LLC
Empowered Funds LLC raised its holdings in Keros Therapeutics, Inc. (NASDAQ: KROS) by 142.2% during the first quarter, according to the company in its most recent filing with the Securities and…
3 months ago zacks.com
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercept pipeline milestones keep attention on future growth.
-
3 months ago benzinga.com
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18
Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $20 to $18.
-
3 months ago benzinga.com
Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.34) by 8.21 percent. This is a 90.79 percent decrease over losses of…
3 months ago globenewswire.com
Keros Therapeutics Reports Second Quarter 2026 Financial Results
LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and…
-
3 months ago benzinga.com
Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS Trial
ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of elritercept versus epoetin alfa for the treatment of anemia due to very low, low, or…
3 months ago globenewswire.com
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel…
3 months ago zacks.com
New Strong Sell Stocks for July 30th
ITRG, BEEM and KROS have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2026.
4 months ago globenewswire.com
Keros Therapeutics Appoints Anne Prener to its Board of Directors
LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and…
4 months ago seekingalpha.com
Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
5 months ago globenewswire.com
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel…
5 months ago zacks.com
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.
-
5 months ago benzinga.com
Keros Therapeutics Q1 EPS $(1.21) Misses $(1.02) Estimate, Sales $367.000K Miss $583.333K Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.21) per share which missed the analyst consensus estimate of $(1.02) by 18.63 percent. This is a 133.43 percent decrease over…
-
7 months ago benzinga.com
Keros Therapeutics Presents Additional Data From Its Phase 1 Clinical Study Of Rinvatercept In Health Volunteers At 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of…
-
8 months ago benzinga.com
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20
Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $23 to $20.
-
8 months ago benzinga.com
CORRECTION: Keros Therapeutics Q4 EPS $(0.86) Misses $(0.60) Estimate, Sales $385.000K Miss $2.757M Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.60) by 42.62 percent. This is a 24.56 percent increase over losses…
8 months ago benzinga.com
Keros Therapeutics: Q4 Earnings Insights
Keros Therapeutics: Q4 Earnings Insights
1 year ago benzinga.com
Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price
Things are hog wild at Harley-Davidson; Plus, Impresoft, Keros Therapeutics and Rivalry Corp. are all itching for a deal.
1 year ago benzinga.com
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
1 year ago benzinga.com
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
-
2 years ago benzinga.com
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
-
2 years ago benzinga.com
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following…
-
2 years ago benzinga.com
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at…
-
2 years ago benzinga.com
Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses in today’s session.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 311 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 647 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 369 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 386 stocks made new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During the session on Thursday, 461 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2023
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2023
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2023
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2023